Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s00280-016-3154-z
Published Online: 2016-09-15
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tamura, Yosuke
Nokihara, Hiroshi
Honda, Kazunori
Tanabe, Yuko
Asahina, Hajime
Yamada, Yasuhide
Enatsu, Sotaro
Kurek, Raffael
Yamamoto, Noboru
Tamura, Tomohide
Funding for this research was provided by:
Eli Lilly and Company
License valid from 2016-09-15